Mechanical and circulating biomarkers in isolated clinic hypertension

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 402-408

  Martin, Catherine ^b   Cameron, James ^b   McGrath, Barry ^a,b  

^a DANDENONG HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Arterial stiffness; Endothelial dysfunction; Inflammation; Isolated clinic hypertension; Oxidative stress

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN 1; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; NITRITE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; VON WILLEBRAND FACTOR;

ALBUMINURIA; ARTERIAL STIFFNESS; ARTERY DISEASE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; LONGITUDINAL STUDY; OXIDATIVE STRESS; PULSE WAVE; URINARY EXCRETION; VASODILATATION;

BIOLOGICAL MARKERS; HUMANS; HYPERTENSION; VASCULAR DISEASES;

EID: 40149091716     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04886.x     Document Type: Conference Paper

References (59)

1. Cuspidi C, Meani S, Sala C et al. How reliable is isolated clinic hypertension defined by a single 24-hr ambulatory blood pressure monitoring? J. Hypertens. 2007 25 : 315 20.
2. McGrath BP. Is white-coat hypertension innocent? Lancet 1996 348 : 630 1.
3. Ugajin T, Hozawa A, Ohkubo T et al. White-coat hypertension as a risk factor for the development of home hypertension: The Ohasama study. Arch. Intern. Med. 2005 165 : 1541 6.
4. Bidlingmeyer I, Burnier M, Bidlingmeyer M, Waeber B, Brunner HR. Isolated office hypertension: A prehypertensive state? J. Hypertens 1996 14 : 327 32.
5. Verdecchia P, Reboldi GP, Agneli F et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005 45 : 203 8.
6. McGrath BP, Laurent S. The current status of arterial functional biomarkers in health and disease. Clin. Exper. Pharmacol. Physiol. 2007 34 : 645 6.
7. Zoungas S, Asmar R. Arterial stiffness and cardiovascular outcome. Clin. Exp. Pharmacol. Physiol. 2007 34 : 647 51.
8. Mancia G, De Backer G, Dominiczak A et al. The Taskforce for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension. J. Hypertens. 2007 25 : 1105 87.
9. Khoshdel AR, Thakkinstian A, Carney SL, Attia J. Estimation of an age-specific reference interval for pulse wave velocity: A meta-analysis. J. Hypertens. 2006 24 : 1231 7.
10. Silva JA, Barbosa L, Bertoquini S, Maldonado J, Polonia J. Relationship between aortic stiffness and cardiovascular risk factors in a population of normotensives, white-coat normotensives, white-coat hypertensives, sustained hypertensives and diabetic patients. Rev. Port. Cardiol. 2004 23 : 1533 47.
11. Ribeiro L, Gama G, Santos A, Asmar R, Martins L, Polonia J. Arterial distensibility in subjects with white-coat hypertension with and without diabetes or dyslipidaemia: comparison with normotensives and sustained hypertensives. Blood Press. Monit. 2000 5 : 11 17.
12. Matsui Y, Eguchi K, Ishikawa J, Hoshide S, Shimada K, Kario K. Subclinical arterial damage in untreated masked hypertensive subjects detected by home blood pressure measurement. Am. J. Hypertens. 2007 20 : 385 91.
13. Longo D, Zaetta V, Perkovic D et al. Impaired arterial elasticity in young patients with white-coat hypertension. Blood Press. Monit. 2006 11 : 243 9.
14. Tillin T, Chambers J, Malik I et al. Measurement of pulse wave velocity: Site matters. J. Hypertens. 2007 25 : 383 9.
15. Pannier B, Guérin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitive and conduit arteries: Prognostic significance for end-stage renal disease patients. Hypertension 2005 45 : 592 6.
16. Gamboa A, Shibao C, Diedrich A et al. Contribution of endothelial nitric oxide to blood pressure in humans. Hypertension, 2007 49 : 170 7.
17. Panza JA, Quyyumi AA, Brush Jr. JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 1990 323 : 22 7.
18. Gomez-Cerezo J, Rios Blanco JJ, Suarez GI et al. Noninvasive study of endothelial function in white coat hypertension. Hypertension 2002 40 : 304 9.
19. Pierdomenico SD, Cipollone F, Lapenna D, Bucci A, Cuccurullo F, Mezzetti A. Endothelial function in sustained and white coat hypertension. Am. J. Hypertens. 2002 15 : 946 52.
20. Karter Y, Erturk NT, Aydin S et al. Endothelial dysfunction in sustained and white coat hypertension. Am. J. Hypertens. 2003 16 : 892.
21. Curgunlu A, Karter Y, Uzun H et al. Hyperhomocysteinemia: An additional risk factor in white coat hypertension. Int. Heart J. 2005 46 : 245 54.
22. Blann AD, W M. Von Willebrand factor and soluble E-selectin in hypertension: Influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis. 1996 7 : 143 7.
23. Kario K, Matsuo T, Kobayashi H et al. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler. Thromb. Vasc. Biol. 1996 16 : 455 61.
24. Coban E, Timuragaoglu A, Ozdogan M. Endothelial dysfunction in patients with white coat hypertension. J. Hum. Hypertens. 2004 18 : 71 2.
25. Karter Y, Aydin S, Curgunlu A et al. Endothelium and angiogenesis in white coat hypertension. J. Hum. Hypertens. 2004 18 : 809 14.
26. Vaindirlis I, Peppa-Patrikiou M, Dracopoulou M, Manoli I, Voutetakis A, Dacou-Voutetakis C. 'White coat hypertension' in adolescents: Increased values of urinary cortisol and endothelin. J. Pediatr. 2000 136 : 359 64.
27. Perticone F, Sciacqua A, Maio R et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J. Am. Coll. Cardiol. 2005 46 : 518 23.
28. Stühlinger MC, Oka RK, Graf EE et al. Endothelial dysfunction induced by hyperhomocysteinemia. Role of asymmetric dimethylarginine. Circulation 2003 108 : 933 8.
29. Coban E, Ozdogan M, Ermis C. Plasma levels of homocysteine in patients with white-coat hypertension. Int. J. Clin. Pract. 2004 58 : 997 9.
30. Pierdomenico SD, Bucci A, Lapenna D et al. Circulating homocysteine levels in sustained and white coat hypertension. J. Hum. Hypertens. 2003 17 : 165 70.
31. Kumar KV, DU. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res. Commun. 1993 19 : 59 66.
32. Cracowski JL, Baguet JP, Ormezzano O et al. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 2003 41 : 286 8.
33. Pierdomenico SD, Costantini F, Bucci A, De Cesare D, Cuccurullo F, Mezzetti A. Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension. Hypertension 1998 31 : 621 6.
34. Caner M, Karter Y, Uzun H et al. Oxidative stress in humans in sustained and white coat hypertension. Int. J. Clin. Pract. 2006 60 : 1565 71.
35. Uzun H, Karter Y, Aydin S et al. Oxidative stress in white coat hypertension; role of paraoxonase. J. Hum. Hypertens. 2004 18 : 523 8.
36. Morrow DA, Rifai N, Antman EM et al. C-reactive protein is a potent predictor of mortality independently of and in combination with Troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in myocardial infarction. J. Am. Coll. Cardiol. 1998 31 : 1460 5.
37. Koenig W, Meisinger C, Baumert J et al. Systemic low-grade inflammation and risk of coronary heart disease: Results from the MONICA/KORA Augsburg cohort studies. Gesundheitswesen 2005 67 (Suppl. 1 S62 7.
38. Albert CM, Ma J, Rifai N et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 105 : 2595 9.
39. Devaraj S, Venugopal S, Jialal I. Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 2006 184 : 48 52.
40. Wang CH, Li SH, Weisel RD et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003 107 : 1783 90.
41. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jiala I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002 106 : 1439 41.
42. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003 290 : 2945 51.
43. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults: The CARDIA study. Arch. Intern. Med. 2006 166 : 345 9.
44. Conen D, Dieterle T, Utech K, Rimner M, Martina B. C-reactive protein and B-type natriuretic peptides in never-treated white coat hypertensives. Hypertens. Res. 2006 29 : 411 15.
45. Schillaci G, Pirro M, Gemelli F et al. Increased C-reactive protein concentrations in never-treated hypertension: The role of systolic and pulse pressures. J. Hypertens. 2003 21 : 1841 6.
46. Erdogan D, Caliskan M, Gullu H et al. Aortic elastic properties and left ventricular diastolic function in white-coat hypertensive individuals. Blood Press. Monit. 2006 11 : 191 8.
47. Devaraj S, Yan Xu D, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Implications for the metabolic syndrome and atherothrombosis. Circulation 2003 107 : 398 404.
48. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: Does it exist? Br. J. Haematol. 1995 90 : 244 8.
49. Srikumar N, Brown NJ, Hopkins PN et al. PAI-1 in human hypertension: Relation to hypertensive groups. Am. J. Hypertens. 2002 15 : 683 90.
50. Poli KA, Tofler GH, Larson MG et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000 101 : 264 9.
51. Wang TJ, Gona P, Larson MG et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007 49 : 432 8.
52. Makris T, Stavroulakis G, Papadopoulos D et al. White coat hypertension and haemostatic/fibrinolytic balance disorders. Eur. Cytokine Net. 2006 17 : 137 41.
53. Coban E, Ozdogan M. The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension. Int. J. Clin. Pract. 2004 58 : 541 4.
54. Martinez MA, Garcia-Puig J, Martin JC et al. Frequency and determinants of white coat hypertension in mild to moderate hypertension. A primary care-based study. Am. J. Hypertens. 1999 12 : 251 9.
55. Pierdemenico SD, Lapenna D, Guglielmi MD et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1999 26 : 801.
56. Palatini P, Mormino P, Santonastaso M et al. Target-organ damage in stage 1 hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 1998 31 : 57 63.
57. Høegholm A, Bang LE, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension and normotension. Hypertension 1994 24 : 101 5.
58. Bang LE, Holm J, Svendsen TL. Retinol-binding protein and transferrin in urine. New markers of renal function in essential hypertension and white coat hypertension? Am. J. Hypertens. 1996 9 : 1024 8.
59. Björklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period. A population-based study of elderly men. Circulation 2002 106 : 63 8.